Nanofármacos

一种覆载绿原酸的人血清白蛋白-硒纳米颗粒的制备方法

Resumen de: CN118557546A

本发明公开了一种覆载绿原酸的人血清白蛋白‑硒纳米颗粒的制备方法，包括如下步骤：S1、以绿原酸、人血清白蛋白为原料，通过偶联反应制备覆载绿原酸的人血清白蛋白；S2、以步骤S1制备的覆载绿原酸的人血清白蛋白为分散剂制备覆载绿原酸的人血清白蛋白‑硒纳米颗粒。本发明一种覆载绿原酸的人血清白蛋白‑硒纳米颗粒的制备方法，利用人血清白蛋白与药物小分子绿原酸进行偶联后，将其作为分散剂稳定纳米硒，不仅可以防止纳米硒聚集，提高其稳定性，还可以高效递送药物小分子绿原酸，提高其水溶性与生物利用度；更重要的是，还可使纳米硒与药物小分子绿原酸协同发挥疗效功能。

膜包被的自组装的纳米药物颗粒、中间体、其制备方法及应用

Resumen de: CN118557547A

本发明提供了膜包被的自组装的纳米药物颗粒、中间体、其制备方法及应用，本申请提供方法制备得到的治疗动脉粥样硬化(AS)的纳米药物颗粒。首先通过自组装单元，尤其是具有两亲性的中药单体成分包裹治疗AS的活性药物成分，形成均匀的纳米药物颗粒；然后再通过细胞膜包被技术将前述颗粒包被在细胞膜内部；细胞膜上具有炎症内皮细胞特异性识别的蛋白分子，可以特异性靶向AS病变部位，通过细胞膜的靶向作用将纳米药物颗粒精准递送到AS病灶部位；同时由于细胞膜上具有细胞免疫识别分子，可以实现免疫逃逸，避免免疫排斥反应；同样避免被清除，提高药物的有效及安全性。

一种响应肿瘤微环境激活且自增效的自发光光动力纳米粒子及其制备方法和应用

Resumen de: CN118557723A

本发明提供一种响应肿瘤微环境激活且自增效的自发光光动力纳米粒子及其制备方法和应用。本发明提供的纳米粒子是一种空间稳定混合胶束，由二硬脂酰磷脂酰乙醇胺‑聚乙二醇2000分子和二油酰基卵磷脂包载鲁米诺‑四苯基卟啉化合物和油酸稳定的过氧化钙纳米粒子制成，该纳米粒子可响应肿瘤微环境的弱酸性pH释放过氧化氢和氧气并通过鲁米诺‑四苯基卟啉化合物介导的化学发光共振能量转移产生活性氧，达到响应肿瘤激活、缓解肿瘤乏氧、基于增效肿瘤原位自发光光动力抑制肿瘤生长和转移的目的。

有效负载递送系统

Resumen de: WO2023084217A1

The disclosure provides a sub-micron particle comprising a first payload molecule, a lipid structure and a plurality of amphiphilic polymer chains surrounding the lipid structure. The first payload molecule is a macromolecule, optionally a nucleic acid. Additionally, the hydrophobicity of the amphiphilic polymer chains changes in response to an external stimulus.

一种用于水痘-带状疱疹病毒预防或治疗的核酸药物及其应用

Resumen de: CN118562831A

本发明提供了一种核酸药物及其制备方法与应用。所述核酸药物的核苷酸序列为SEQ ID NO:2‑5中的一种或几种。所述核酸药物具有高的T细胞应答能力和诱导gE特异性记忆B细胞生成能力，为水痘‑带状疱疹的预防和治疗提供了新的途径，降低了罹患带状疱疹及其并发症引的风险。

磁驱微纳米机器人异构集群基于pH映射递送药物的方法

Resumen de: CN118571409A

本发明公开了一种磁驱微纳米机器人异构集群基于pH映射递送药物的方法，属于微纳米机器人技术领域。本发明构建了由传感微纳米机器人和载药微纳米机器人组成的异构集群，在磁场操控下，两种微纳米机器人可以形成微纳米机器人异构集群，并在未知环境中主动巡航。同时，集群中的传感微纳米机器人可以利用其pH响应结构色对周围环境进行实时pH映射，并在遭遇酸性靶标时产生结构色变化，映射/绘制局部pH值分布图，从而报告靶标的存在和位置；利用此pH映射结果作为视觉反馈，可以引导异构集群在外部交变磁场操控下运动到达并覆盖检测到的靶标，从而将载药微纳机器人精准递送到靶标区域。

自噬抑制剂协同电动力疗法的纳米材料及制备方法和应用

Resumen de: CN118557545A

本发明涉及一种自噬抑制剂协同电动力疗法的纳米材料，涉及新材料领域。该纳米材料包括自噬抑制剂和载体，载体为铂铱纳米颗粒，自噬抑制剂与载体中铂的质量比为1：(7‑13)。利用该纳米材料，通过调控免疫微环境以及实现增强的电动力治疗共同发挥对肿瘤的长期抑制作用，实现对大体积肿瘤的有效治疗，为电动力疗法进行协同治疗提供新策略。

用作乳化剂和药物载体的白蛋白

Resumen de: AU2022376283A1

The present disclosure is directed to methods of using albumin as an emulsifier to assist in blending otherwise immiscible components. Methods use albumin as an emulsifier and a carrier. The disclosure also teaches utilization of albumin as a microencapsulating liquid, gel or powder and as a drug or nutraceutical carrier wherein bioavailability is increased.

用于蛋白质表达和细胞分化的方法和组合物

Resumen de: AU2022395910A1

Provided herein are methods and compositions for alteration of protein expression that can result in cell differentiation or production of proteins of biopharmaceutical relevance or engineered cells for use as therapeutic medicinal products. The compositions may comprise a saccharide, a nucleic acid molecule, and/or a polymeric material. The compositions and methods may promote or facilitate uptake of a nucleic acid by a cell. The compositions and methods may promote or facilitate differentiation of the cell.

编码HTNV包膜糖蛋白GP的基因、其编码的表达载体、mRNA分子及其用途

Resumen de: CN118562832A

本发明属于核酸疫苗技术领域，具体涉及一种编码HTNV包膜糖蛋白GP的基因、其编码的表达载体、mRNA分子及其用途。该基因的核苷酸序列SEQ ID NO.1所示。将该基因插入pVAX1载体中构建pVAX1‑GPHTNV。将pVAX1‑GPHTNV封装在LNP中，构成LNP‑GPDNA疫苗。在该基因上增加了UTR及聚腺苷酸尾后，将其插入pGEM‑UTR载体构建pGEM‑UTR‑GPHTNV，再通过体外转录及加帽修饰得到mRNA分子，构成GPmRNA疫苗。动物实验证实，三种疫苗均能够有效诱导抗汉坦病毒特异性细胞和体液免疫应答，具有良好的体内攻毒保护效果、体外中和活性以及应用安全性。

聚合前药、仿生纳米聚合前药、其制备方法及应用

Resumen de: CN118557741A

聚合前药、仿生纳米聚合前药、其制备方法及应用，属于生物学工程领域。本申请制备方法制备得到的仿生纳米聚合前药，通过具有细胞膜成分的膜包被纳米前药，尤其是使用细胞外囊泡膜，通过中性粒细胞外囊泡的“伪装”减少机体免疫系统的清除，延长体内循环时间；并在中性粒细胞外囊泡特异性识别CIRI部位作用下跨BBB高效聚集到CIRI病变部位，继而响应高ROS微环境释放PB药物，实现清除ROS、抗炎以及保护神经元细胞的功能，从而最终达到安全、高效治疗CIRI的目的。

一种高渗透纳米载药体系的通用合成方法与应用

Resumen de: CN118557544A

本发明涉及一种高渗透纳米载药体系的通用合成方法与应用，属于生物医药技术领域。具体的说，利用疏水性药物介导聚乙二醇‑15‑羟基硬脂酸酯(HS)共组装获得具有组织穿透性的纳米载药体系，其不仅能快速穿过细胞膜进入细胞，还能在细胞间快速传递，并在脂肪，肿瘤组织中展现出高的渗透作用。本发明不仅能实现多种疏水性药物的共组装加载，还能实现肿瘤，肥胖等多种疾病的协同治疗应用。

一种通过优化全长结构蛋白序列设计的基孔肯雅病毒广谱性mRNA疫苗

Resumen de: CN118561969A

本发明属于mRNA疫苗制备技术领域，具体涉及一种通过优化全长结构蛋白序列设计的基孔肯雅病毒广谱性mRNA疫苗，具体的，本发明提供一种多核苷酸，所述多核苷酸序列如SEQ ID NO.2所示，所述mRNA疫苗中含SEQ ID NO.2所示序列转录获得的mRNA，本发明提供的疫苗具有更强烈的细胞免疫应答水平，剂量达到一定水平后产生的结合抗体水平更高维持的更加持久，并且中和抗体水平也具有一定作用，在广谱性上，疫苗对来自西非谱系、印度洋谱系与东中南非谱系的假病毒产生中和抗体，具有交叉保护性。

一种靶向根除耐药幽门螺杆菌的多功能级联纳米酶及其制备方法和用途

Resumen de: CN118557548A

本发明公开了一种可靶向根除耐药幽门螺杆菌（H.pylori）的多功能纳米酶的制备方法和应用，属于纳米技术领域。该纳米酶（FPB‑Co‑Ch）由包覆了Co3O4纳米粒子的新型普鲁士蓝类似物再修饰壳聚糖制备得到。通过对该制剂的多酶活性进行测定，得到该复合纳米粒子具有pH选择性的氧化酶（OXD）、过氧化物酶（POD）、过氧化氢酶（CAT）及超氧化物歧化酶（SOD）活性；这些多酶活性促使该纳米酶能够在胃酸环境（pH 1.3）中持续产生大量O2以及·OH，从而抑制对氧气敏感的H.pylori的生长。通过H.pylori的体外清除实验，发现该复合纳米酶在胃酸环境（pH 1.3）的抑菌效果良好；通过模拟胃环境耐受性实验，发现该复合纳米酶在胃液中具有很好的稳定性；通过动物实验，发现该纳米酶抗菌活性明显优于其他对照组纳米材料，其能够特异性作用于胃内酸性环境，能够有效预防并根除H.pylori感染导致的疾病。同时，该纳米酶可通过分解H2O2及·O2‑清除ROS，来缓解由于感染H.pylori引起的胃黏膜炎症反应。

CATIONIC LIPIDS AND COMPOSITIONS THEREOF

Resumen de: US2024285796A1

Provided herein are lipids having the Formula I or Formula Ia:and pharmaceutically acceptable salts thereof, wherein R′, R1, R2, R3, R4, R5, R6a, R6b, X1, X2, and n are as defined herein for Formula I and Formula Ia, respectively. Also provided herein are lipid nanoparticle (LNP) compositions comprising lipid having the Formula I or Ia and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).

COMPOSITIONS AND METHODS FOR TREATING CANCER

Resumen de: US2024285740A1

This disclosure features human Lymphocyte-activation gene 3 (LAG3) and human Galectin-3 (GAL3) inhibitory agents, immunogenic peptides X-Box Binding Protein 1 (XBP1), CD2 Subset 1 (CS1), and CD138 peptides, and methods of using the inhibitory agents and peptides to treat blood cancers and pre-cancerous conditions.

TREATMENT OF PRIMARY CILIARY DYSKINESIA WITH SYNTHETIC MESSENGER RNA

Resumen de: US2024285798A1

Polynucleotides encoding peptides, proteins, enzymes, and functional fragments thereof are disclosed. The polynucleotides of the disclosure can be effectively delivered to an organ, such as the lung, and expressed within cells of the organ. The polyribonucleotides of the disclosure can be used to treat a disease or condition associated with cilia maintenance and function, impaired function of the axoneme, such as DNAI1 or DNAH5.

BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS

Resumen de: US2024285768A1

The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

BIODEGRADABLE POLYMER COMPRISING SIDE CHAINS WITH POLYAMINE AND POLYALKYLENE OXIDE GROUPS

Resumen de: US2024285781A1

Provided is a polymer comprising a hydrolysable polymer backbone, the polymer backbone comprising: (i) monomer units comprising a hydrophobic side chain; (ii) monomer units comprising a side chain comprising a polyamine group and a polyalkylene oxide group; and, optionally, (iii) monomer units comprising a side chain comprising a polyamine group without a polyalkylene oxide group, as well as a method of preparing said polymer, and a method of delivering a nucleic acid and/or polypeptide to a cell using the polymer.

BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS

Resumen de: US2024285767A1

The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

MRNA VACCINES ENCODING FLEXIBLE CORONAVIRUS SPIKE PROTEINS

Resumen de: US2024285754A1

The disclosure provides mRNA vaccines which encode for coronavirus spike proteins exhibiting increased flexibility in the crown of the helix turn region. This increased flexibility is achieved by at least two glycine mutations within the crown of the helix turn region, located between the HR1 and CH regions.

MRNA DELIVERY METHOD AND COMPOSITION THEREOF

Resumen de: US2024285544A1

The present disclosure provides a lipid nanoparticle for extrahepatic delivery of mRNA, the lipid nanoparticle comprising: (i) mRNA cargo; (ii) a phosphatidylcholine lipid content of from 30 mol % to 70 mol %; (iii) a ionizable, cationic lipid content of from 5 mol % to 50 mol %; (iv) a sterol selected from cholesterol or a derivative thereof; and (v) a hydrophilic polymer-lipid conjugate that is present at a lipid content of 0.5 mol % to 5 mol. Further provided is a lipid nanoparticle comprising encapsulated mRNA and 20 to 70 mol % of a phosphatidylcholine lipid, an ionizable lipid; and at least one of a sterol and a hydrophilic polymer-lipid conjugate, the lipid nanoparticle exhibiting at least a 10% increase in gene expression of the mRNA in vivo as measured in one or more extrahepatic organs or tissues. Further provided are methods of administration of such lipid nanoparticles.

NANOPARTICLES WITH ANTI-INFLAMMATORY PROPERTIES AND ENHANCED PENETRATION ACROSS THE BIOLOGICAL BARRIERS TO DELIVER ENCAPSULATED DRUGS

Resumen de: US2024285575A1

Disclosed herein are compositions of nanoparticles with naringenin as a folate receptor (FR)-targeting ligand and methods of making and administering the nanoparticles with naringenin (NAR) ligands for drug delivery applications. The disclosed compositions include NAR-functional polyester-based nanoparticles encapsulating insulin (i.e. insulin-laden NAR-functional nanoparticles), which showed loading capacities of 10% and encapsulation efficiency of >70%. The insulin-laden NAR-functional nanoparticles are shown in examples to have a 3-fold higher bioavailability of insulin compared to unfunctionalized nanoparticles, suggesting the role of receptor-mediated transport across the intestinal barriers. Methods of making NAR-functional nanoparticles are also disclosed herein, and methods of administration for the peroral delivery of encapsulated drugs.

NANOPARTICLE-MEDIATED ENHANCEMENT OF IMMUNOTHERAPY TO PROMOTE FERROPTOSIS-INDUCED CYTOTOXICITY AND ANTITUMOR IMMUNE RESPONSES

Resumen de: US2024285543A1

Described herein are methods of treating cancer by administering to a subject a composition comprising ultrasmall silica nanoparticles to enhance one or more of the following immunotherapies: chimeric antigen receptor (CAR) T-cell therapy, immune checkpoint blockade antibody therapy (ICB), immune inhibitor therapy (e.g., myeloid-targeting inhibitors). In some embodiments, the compositions are used in combination with external beam radiotherapy.

METHODS AND MATERIALS FOR TREATING CANCER

Nº publicación: US2024285525A1 29/08/2024

Solicitante:

THE JOHNS HOPKINS UNIV [US]
The Johns Hopkins University

Resumen de: US2024285525A1

This document relates to methods and materials for treating cancer. For example, nanostructures (e.g., nanotubes) having one or more anti-cancer agents intercalated in the nanostructures are provided. In some cases, nanostructures (e.g., nanotubes) having one or more anti-cancer agents intercalated in the nanostructures can be administered to a mammal (e.g., a human) having cancer to treat the mammal.